Press Releases for VRX

Press Releases
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on VRX, BBV, GMR, PRE, DB and PZE
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
Valeant Pharmaceuticals Reports Second Quarter Financial Results
Valeant to Acquire Tecnofarma, A Mexican Generic Company
Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009
Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(R) ER in Canada, Australia and New Zealand; Agreement Demonstrates Value of OPANA ER in Markets Outside U.S.
Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
Valeant Announces Pricing of Senior Notes
Valeant Pharmaceuticals to Present at Goldman Sachs 30th Annual Global Healthcare Conference
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
Valeant Announces Increase to Securities Repurchase Program
Valeant Plans Senior Notes Offering
Valeant Pharmaceuticals to Webcast 2009 Annual Meeting of Stockholders
Valeant Pharmaceuticals Reports First Quarter Financial Results
Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
Valeant Pharmaceuticals Appoints Steve Stefano of GlaxoSmithKline to Fill Board Vacancy
Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
Orthofix International Sends Letter to Shareholders Opposing A Second Ramius Board Nominee
Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
Valeant Pharmaceuticals to Present at Roth 21st Annual OC Growth Stock Conference
Valeant Pharmaceuticals Appoints Anders Lonner of Meda to Fill Board Vacancy
Dow Pharmaceutical Sciences Becomes Wholly Owned Subsidiary as Acquisition by Valeant Pharmaceuticals International is Completed
Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
Valeant Pharmaceuticals to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Valeant Reports Encouraging End of Treatment Results with Taribavirin at Treatment Week 48 in Phase IIb Study
Valeant Pharmaceuticals Acquires DermaTech
Valeant Pharmaceuticals to Present at Lazard Capital Markets 5th Annual Healthcare Conference
Valeant Pharmaceuticals to Present at 2008 Credit Suisse Phoenix Health Care Conference
Valeant Pharmaceuticals Reports Third Quarter Financial Results
Valeant Pharmaceuticals Announces Promotion Agreement for Diastat(R) AcuDial(TM)
Valeant Pharmaceuticals to Announce 2008 Third Quarter Results on November 6, 2008
Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine
Valeant Pharmaceuticals Completes Acquisition of Coria Laboratories, Ltd.
DFB Sells Coria Labs to Valeant Pharmaceuticals
Valeant Pharmaceuticals Signs Agreement to Acquire Coria Laboratories, Ltd.
Valeant Announces Presentation of Retigabine Data at the 8th European Congress on Epileptology
Valeant Pharmaceuticals Completes Sale of Certain European Operations to Meda AB
Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine
Valeant Pharmaceuticals to Present at UBS Global Life Sciences Conference
Valeant Pharmaceuticals Reports Second Quarter Financial Results
Meda Enters into Joint Venture with Valeant
Valeant Announces Agreement to Enter into Joint Venture with Meda
Valeant Sells Certain Business Operations in Europe for $392 Million
Valeant Pharmaceuticals to Announce 2008 Second Quarter Results on August 11, 2008
Valeant Announces Redemption of All Outstanding 7% Senior Notes Due 2011
Valeant Pharmaceuticals Announces Increase in Share Repurchase Authorization
Valeant Pharmaceuticals Divests Argentina
Valeant Pharmaceuticals to Present at Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
Valeant Pharmaceuticals to Webcast 2008 Annual Meeting of Stockholders - May 27 2008 12:57AM
Valeant Pharmaceuticals Announces FDA Has Initiated Reconsideration of Generic Efudex(R) Approval - May 27 2008 12:54AM
Valeant Announces Successful Completion of Retigabine Phase III Epilepsy Program Validating Novel Mechanism of Action - Jun 2 2008 2:18AM
Valeant Pharmaceuticals Reports 2008 First Quarter Financial Results - Jun 2 2008 2:18AM
Valeant Pharmaceuticals Announces Temporary Stay in Efudex(R) Case - Jun 2 2008 2:18AM
Valeant Pharmaceuticals Reduces Headcount - Jun 2 2008 2:18AM
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Valeant Pharmaceuticals to Announce 2008 First Quarter Results on May 7, 2008